How To Use CPT Code 0307U

CPT 0307U describes the next-generation targeted sequencing analysis of a patient-specific panel using cell-free DNA to evaluate for minimal residual disease (MRD) in oncology. This article will cover the official description, procedure, qualifying circumstances, appropriate usage, documentation requirements, billing guidelines, historical information, and examples of CPT code 0307U.

1. What is CPT Code 0307U?

CPT 0307U can be used to describe the next-generation targeted sequencing analysis of a patient-specific panel using cell-free DNA to evaluate for minimal residual disease (MRD) in oncology. This code is used when clinicians perform a subsequent assessment with comparison to previously analyzed patient specimens to determine the presence of MRD following cancer treatment.

2. Official Description

The official description of CPT code 0307U is: ‘Oncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis of a patient-specific panel, cell-free DNA, subsequent assessment with comparison to previously analyzed patient specimens to evaluate for MRD.’

3. Procedure

1. Clinicians collect a blood specimen from the patient.
2. The specimen is analyzed using Invitae’s Anchored Multiplex polymerase chain reaction (PCR) technique called AMP™.
3. The analysis evaluates the patient’s blood specimen for circulating tumor DNA (ctDNA) sequences related to the patient’s tumor profile identified in a prior test.
4. The level of ctDNA present in the blood specimen is assessed to determine the presence of minimal residual disease (MRD).
5. Subsequent blood tests may be performed to monitor the level of ctDNA and identify cancer recurrence earlier than imaging diagnostics can.

4. Qualifying circumstances

CPT 0307U is used for patients who have previously undergone a test (CPT code 0306U) to develop their individualized tumor profile. The subsequent assessment using CPT code 0307U is performed to evaluate for minimal residual disease (MRD) and monitor patients for cancer recurrence. This code is specific to the Invitae PCM MRD Monitoring test from Invitae Corporation.

5. When to use CPT code 0307U

CPT code 0307U should be used when clinicians perform a subsequent assessment using next-generation targeted sequencing analysis of a patient-specific panel to evaluate for minimal residual disease (MRD) in oncology. This code should not be reported in conjunction with CPT code 0306U, as they represent different stages of testing.

6. Documentation requirements

To support a claim for CPT code 0307U, clinicians must document the following information:

• Indication for the test and the need to evaluate for minimal residual disease (MRD)
• Details of the patient-specific panel used for analysis
• Date of the subsequent assessment
• Comparison to previously analyzed patient specimens
• Results of the analysis and interpretation of the presence or absence of MRD
• Signature of the clinician performing the assessment

7. Billing guidelines

When billing for CPT code 0307U, ensure that the test is performed using the Invitae PCM MRD Monitoring test from Invitae Corporation. Report one unit of this code for a single specimen analyzed on a single date of service. Do not report CPT code 0306U and 0307U together, as they represent different stages of testing. Some payers may separately reimburse for specimen collection.

8. Historical information

CPT code 0307U was added to the Current Procedural Terminology system on April 1, 2022. There have been no updates to the code since its addition.

9. Examples

1. A patient previously underwent a test (CPT code 0306U) to develop their individualized tumor profile. Clinicians performed a subsequent assessment using CPT code 0307U to evaluate for minimal residual disease (MRD) and monitor for cancer recurrence.
2. Following cancer treatment, a patient’s blood specimen was analyzed using next-generation targeted sequencing analysis of a patient-specific panel (CPT code 0307U). The assessment identified the presence of minimal residual disease (MRD) and guided the decision for adjuvant cancer therapy.
3. Clinicians collected a blood specimen from a patient who had previously undergone a test to develop their individualized tumor profile. The subsequent assessment using CPT code 0307U revealed no evidence of minimal residual disease (MRD), indicating a successful response to cancer treatment.
4. A patient with a history of cancer underwent regular blood tests using CPT code 0307U to monitor for minimal residual disease (MRD) and detect cancer recurrence at an early stage.
5. Following cancer treatment, a patient’s blood specimen was analyzed using next-generation targeted sequencing analysis of a patient-specific panel (CPT code 0307U). The subsequent assessment revealed the presence of minimal residual disease (MRD), prompting further evaluation and treatment decisions.
6. Clinicians performed a subsequent assessment using CPT code 0307U to evaluate for minimal residual disease (MRD) in a patient who had previously undergone a test to develop their individualized tumor profile. The assessment provided valuable information for monitoring the patient’s response to treatment and detecting potential cancer recurrence.
7. Regular blood tests using CPT code 0307U were performed on a patient with a history of cancer to monitor for minimal residual disease (MRD) and assess the effectiveness of treatment.
8. A patient’s blood specimen was analyzed using next-generation targeted sequencing analysis of a patient-specific panel (CPT code 0307U). The subsequent assessment revealed no evidence of minimal residual disease (MRD), indicating a favorable response to cancer treatment.
9. Clinicians collected a blood specimen from a patient who had previously undergone a test to develop their individualized tumor profile. The subsequent assessment using CPT code 0307U showed the presence of minimal residual disease (MRD), prompting further evaluation and treatment adjustments.
10. Following cancer treatment, regular blood tests using CPT code 0307U were performed to monitor for minimal residual disease (MRD) and detect any signs of cancer recurrence.